Vistagen plans revised Phase 3 fasedienol study for social anxiety disorder after FDA feedback
VTGN•Vistagen plans to revise a future Phase 3 trial of fasedienol for social anxiety disorder after FDA feedback. The trial will target the general patient population and assess longer-term functional improvement using the Liebowitz Social Anxiety Scale as its primary endpoint.
1. Planned trial changes
Vistagen plans to revise a future Phase 3 study of fasedienol for social anxiety disorder following FDA feedback. The study will target the general patient population and overall treatment, rather than acute treatment alone, and assess whether acute effects translate into longer-term functional improvement using the Liebowitz Social Anxiety Scale as its primary endpoint. The FDA recognized fasedienol’s reported safety profile and potential to benefit a broad patient population.
